ABOUT US
ABOUT US
ConVerd, located at the Hangzhou Future SCI-Tech City, is an innovative biotech company focused on oncolytic viruses (OV) and other cancer immunotherapies. Dr. Fang Hu, the founder and CEO of ConVerd, has led the successful development of the world's first oncolytic virus drug, Oncorine ®, which was approved in China in 2005. ConVerd has a team of talented and experienced professionals with expertise that covers the entire new drug development process from bench to bed. Supported by strategic investments from Morningside and China Resources Group, ConVerd has established R&D platforms for three new generation oncolytic virotherapies. Guided by the rationale for systemic immunotherapy, ConVerd also puts great effort into exploring optimal combinations of OV and other immunotherapies. ConVerd has filed 81 patent applications in the field of cancer immunotherapy in China and other countries.
NEWS
NEWS
- Dec202222On Dec. 21, 2022, the Investigational New Drug (IND) Application of V01, the first oncolytic vaccinia virus product independently innovated by Converd, was accepted by Center For Drug Evaluation, NMPA.
- Sep201921The latest results of a NKG2D-CAR-NK's clinical stuy, conducted by ConVerd's subsidiary and a team led by Hu Xv who is the president of the 3rd hospital of Guangzhou Medical University, were publishe in the journal, Molecular Therapy.
- Apr201912Recently, Hangzhou ConVerd Co., Ltd. made its debut at the 2019 Annual Meeting of the American Association for Cancer Research (AACR Annual Meeting 2019)
- Mar201920On Mar.18, 2019, Cold Genesys, an American company developing a form of cancer immunotherapy using genetically engineered viruses, has closed a $22 million round of funding.